caa a22 4500 606235817 CHVBK 20210128101244.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s11010-015-2545-5 doi (NATIONALLICENCE)springer-10.1007/s11010-015-2545-5 The role of FGF2 in migration and tubulogenesis of endothelial progenitor cells in relation to pro-angiogenic growth factor production [Elektronische Daten] [Monika Litwin, Agata Radwańska, Maria Paprocka, Claudine Kieda, Tadeusz Dobosz, Wojciech Witkiewicz, Dagmara Baczyńska] In recent years, special attention has been paid to finding new pro-angiogenic factors which could be used in gene therapy of vascular diseases such as critical limb ischaemia (CLI). Angiogenesis, the formation of new blood vessels, is a complex process dependent on different cytokines, matrix proteins, growth factors and other pro- or anti-angiogenic stimuli. Numerous lines of evidence suggest that key mediators of angiogenesis, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) together with fibroblast growth factor2 (FGF2) are involved in regulation of the normal and pathological process of angiogenesis. However, less information is available on the complex interactions between these and other angiogenic factors. The aim of this study was to characterise the effect of fibroblast growth factor2 on biological properties of human endothelial progenitor cells with respect to the expression level of other regulatory cytokines. Ectopic expression of FGF2 in EP cells stimulates their pro-angiogenic behaviour, leading to increased proliferation, migration and tube formation abilities. Moreover, we show that the expression profile of VEGF and other pro-angiogenic cytokines, such as HGF, MCP2, and interleukins, is affected differently by FGF2 in EPC. In conclusion, we provide evidence that FGF2 directly affects not only the biological properties of EP cells but also the expression pattern and secretion of numerous chemocytokines. Our results suggest that FGF2 could be applied in therapeutic approaches for CLI and other ischaemic diseases of the vascular system in vivo. Springer Science+Business Media New York, 2015 Endothelial progenitor cells nationallicence Basic fibroblast growth factor nationallicence Angiogenesis nationallicence Cytokines nationallicence Vascular endothelial growth factor nationallicence CLI : Critical limb ischaemia nationallicence EPCs : Endothelial progenitor cells nationallicence FGF2 : Basic fibroblast growth factor nationallicence FGFR : Fibroblast growth factor receptor nationallicence GAPDH : Glyceraldehyde 3-phosphate dehydrogenase nationallicence HGF : Hepatocyte growth factor nationallicence HGFR : Hepatocyte growth factor receptor nationallicence MCP2 : Monocyte chemoattractant protein-2 nationallicence PBS : Phosphate buffered saline nationallicence RT-PCR : Real-time polymerase chain reaction nationallicence VEGF : Vascular endothelial growth factor nationallicence VEGFR : Vascular growth factor receptor nationallicence Litwin Monika WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut Radwańska Agata WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut Paprocka Maria WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut Kieda Claudine Centre de Biophysique Moléculaire, CNRS, 45071, Orléans Cedex 2, France aut Dobosz Tadeusz WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut Witkiewicz Wojciech WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut Baczyńska Dagmara WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 410/1-2(2015-12-01), 131-142 0300-8177 410:1-2<131 2015 410 11010 https://doi.org/10.1007/s11010-015-2545-5 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-015-2545-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Litwin Monika WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut NATIONALLICENCE 700 1- Radwańska Agata WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut NATIONALLICENCE 700 1- Paprocka Maria WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut NATIONALLICENCE 700 1- Kieda Claudine Centre de Biophysique Moléculaire, CNRS, 45071, Orléans Cedex 2, France aut NATIONALLICENCE 700 1- Dobosz Tadeusz WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut NATIONALLICENCE 700 1- Witkiewicz Wojciech WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut NATIONALLICENCE 700 1- Baczyńska Dagmara WroVasc — Integrated Cardiovascular Centre, Regional Specialist Hospital, Research and Development Centre, Kamienskiego 73a, Wrocław, Poland aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 410/1-2(2015-12-01), 131-142 0300-8177 410:1-2<131 2015 410 11010